RxDoctor Payments DataLook up a doctor →

John Ellerton, MD

Hematology & Oncology · Las Vegas, NVNPI 1962585745

Payments from drug & device makers

$90,017in general payments, 2019–2025

Across 683 payments — averaging $131.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$33K
  • Novocure GmbH$23K
  • Amgen$11K
  • Merck$4K
  • Bristol Myers Squibb$4K
  • EMD Serono, Inc.$4K
  • plus $12K from 49 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation67$33,143
Novocure GmbH6$22,706
Amgen80$10,682
Merck72$4,214
Bristol Myers Squibb19$3,664
EMD Serono, Inc.21$3,606
Bayer13$3,240
Acerta Pharma LLC1$2,275
Novartis64$639
Regeneron Healthcare Solutions, Inc.27$526
Pfizer53$478
Johnson & Johnson(2 entities)28$384
Genentech USA, Inc.25$383
Sanofi21$365
Seagen Inc.16$365
Daiichi Sankyo Inc.28$348
E.r. Squibb & Sons, L.L.C.17$303
AstraZeneca(2 entities)15$250
Pharmacyclics LLC, An Abbvie Company6$211
Gilead(2 entities)12$195
Eisai Inc.9$194
Aurobindo Pharma USA, Inc.1$178
Sobi, Inc5$163
Rigel Pharmaceuticals, Inc.6$137
Astellas Pharma US Inc8$135
Sanofi-aventis U.S. LLC1$100
Myovant Sciences Inc.5$95
Global Blood Therapeutics, Inc.4$88
Karyopharm Therapeutics Inc.4$75
Sun Pharmaceutical Industries Inc.3$68
Clovis Oncology, Inc.7$66
Puma Biotechnology, Inc.3$58
Tesaro, Inc.2$58
Dendreon Pharmaceuticals LLC2$51
Exelixis Inc.3$51
AMAG Pharmaceuticals, Inc.2$50
Boehringer Ingelheim2$45
Array Biopharma Inc3$45
Takeda Pharmaceuticals U.S.A., Inc.3$41
Beigene USA, Inc.2$41
Taiho Oncology, Inc.2$39
Servier Pharmaceuticals LLC2$33
Ipsen Biopharmaceuticals, Inc1$24
Epizyme, Inc.1$23
Blue Earth Diagnostics1$20
Genmab U.S., Inc.1$20
Spectrum Pharmaceuticals Inc.1$19
Verastem, Inc.1$18
Chiesi USA, Inc.1$18
Agios Pharmaceuticals, Inc.1$18
GSK1$16
Pharmacosmos Therapeutics Inc.1$15
Novocure Inc.1$14
EUSA Pharma (US) LLC1$13
Teva Pharmaceuticals USA, Inc.1$11

How this compares

$90,017 in reported general payments places this provider in the 65th percentile of 82 hematology & oncology providers in Nevada.

See all hematology & oncology providers in Nevada →

Medicare billing

Part B allowed, 2024
$242,504
Medicare patients
68
Services billed
12,871

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →